Inclusion Criteria:

- Female patient aged ≥ 18 years

- Women with histologically proven non metastatic breast cancer

- ECOG PS ≤ 1

- Patient receiving adjuvant hormonal therapy for at least 1 month (aromatase inhibitor
or Tamoxifen ± ovarian function suppression (Luteinizing Hormone Releasing Hormone
agonist (LH-RH agonist), ovariectomy...))

- Patient complaining of hot flashes with moderate to severe intensity, affecting
quality of life, for at least 1 month before inclusion

- Patient agreement not to start another hot flash treatment during the study
(allopathic treatment, E vitamin, dietary supplement, phytotherapy, acupuncture...)

- Patient able to understand, read and write French

- Mandatory affiliation with a health insurance system

- Signed, written informed consent

Exclusion Criteria:

- Ongoing chemotherapy or radiotherapy, or treatment planned to begin during the study

- Patient with a condition known to induce hot flashes such as hyperthyroidism,
diabetes, adrenal tumor, enteric carcinoid tumor, mastocytosis...

- Patient with severe renal failure, severe hepatic failure, or cardiovascular disease

- Patient with one of the following contraindications:

- known hypersensitivity to one of the components of the study drug

- galactose, fructose intolerance

- Lapp lactase deficiency, isomaltase invertase deficiency

- Glucose or galactose malabsorption syndrome

- Follow up impossible because of social, familial, geographical or psychological
reasons

- Patient suspected of poor compliance with protocol or treatment

- Participation in another biomedical research trial in the same indication, or
administration of an experimental drug in the same indication in the 30 days before
inclusion